Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 111-IN-hPAM4, MUC-1 antibody, IMMU-107 (hPAM4), hPAM4, IMMU-107, anti-mucin antibody
90Y-hPAM4 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| multiple dose levels | EXPERIMENTAL | 1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine. |
| Multi Dose levels | EXPERIMENTAL | different doses of 90YhPAM4 will be given only once. |
| Name | Type | Description |
|---|---|---|
| IMMU-107 (hPAM4) | BIOLOGICAL | 90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks |
| 90Y-hPAM4 | BIOLOGICAL | Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks. |
Inclusion Criteria: * Male or female patients, \>18 years of age, who are able to understand and give written informed consent. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Stage III (locally advanced, unresectable) or Stage IV (metastatic) disease, including patients wh...
Top 20 of 69 competitors
90Y-hPAM4 is an investigational monoclonal antibody being studied for the treatment of pancreatic cancer. It is a radiolabeled antibody designed to deliver radiation directly to cancer cells. As of the available data, it is in Phase 1 clinical development and has not been approved by regulatory authorities.
90Y-hPAM4 is a monoclonal antibody that targets a specific antigen associated with pancreatic cancer cells. The antibody is labeled with the radioisotope yttrium-90, which delivers targeted radiation to the tumor. This approach aims to concentrate the therapeutic effect at the cancer site while sparing normal tissues.
90Y-hPAM4 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 1 clinical trials for pancreatic cancer, and its development is part of Gilead's oncology pipeline.
90Y-hPAM4 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The Phase 1 trial was designed to evaluate the safety and efficacy of different doses of the drug in patients with pancreatic cancer.
90Y-hPAM4 has one completed clinical trial registered under NCT00597129, titled 'Safety and Efficacy Study of 90Y-hPAM4 at Different Doses.' This Phase 1 study enrolled 21 participants with pancreatic cancer in the United States. The trial was not randomized or blinded and did not use a control group.